Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI; Marianne Brodmann, MD; Keith Sterling, MD
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
Zola N'Dandu, MD, discusses one of the presentations he gave at the 2026 Amputation Prevention Symposium on what is needed to successfully perform deep venous arterialization.
Zola N'Dandu, MD, discusses one of the presentations he gave at the 2026 Amputation Prevention Symposium on what is needed to successfully perform deep venous arterialization.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
Dr Luis Sanchez discusses patient selection criteria for treatment of thoracoabdominal aortic aneurysms and his experiences with the GORE® EXCLUDER® TAMBE.
Dr Luis Sanchez discusses patient selection criteria for treatment of thoracoabdominal aortic aneurysms and his experiences with the GORE® EXCLUDER® TAMBE.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
A 2026 retrospective study of patients with solitary unresectable hepatocellular carcinoma found that transarterial radioembolization was associated with longer adjusted overall survival and local progression-free survival than transarterial...
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI; Marianne Brodmann, MD; Keith Sterling, MD
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Drs Secemsky, Brodmann, and Sterling review the evolution of the paclitaxel discussion, examine contemporary evidence from clinical trials and real-world studies.
Zola N'Dandu, MD, discusses one of the presentations he gave at the 2026 Amputation Prevention Symposium on what is needed to successfully perform deep venous arterialization.
Zola N'Dandu, MD, discusses one of the presentations he gave at the 2026 Amputation Prevention Symposium on what is needed to successfully perform deep venous arterialization.
Dr Luis Sanchez discusses patient selection criteria for treatment of thoracoabdominal aortic aneurysms and his experiences with the GORE® EXCLUDER® TAMBE.
Dr Luis Sanchez discusses patient selection criteria for treatment of thoracoabdominal aortic aneurysms and his experiences with the GORE® EXCLUDER® TAMBE.
Naina G. Subherwal; Simran P. Subherwal; Sreejit Nair, MD; Ashwani Sastry, MD
This review synthesized 31 studies (99,600 day case procedures; 2000-2024) plus U.S. registries and real-world cohorts evaluating outpatient peripheral endovascular intervention (PVI) for peripheral arterial disease.
This review synthesized 31 studies (99,600 day case procedures; 2000-2024) plus U.S. registries and real-world cohorts evaluating outpatient peripheral endovascular intervention (PVI) for peripheral arterial disease.
Global pioneer of embolotherapy and leading U.S. interventional radiologist join forces with CUC America to build a scalable Office-Based Laboratory (OBL) platform
New Baltimore, MI — April 9, 2026 — CUC America, a leading provider of...
Global pioneer of embolotherapy and leading U.S. interventional radiologist join forces with CUC America to build a scalable Office-Based Laboratory (OBL) platform
New Baltimore, MI — April 9, 2026 — CUC America, a leading provider of...
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Mike Watts, MD, FSIR, from Atlantic Medical Imaging in New Jersey, presented a practical, real-world approach to performing distal deep venous arterialization (dDVA) in the office-based lab.
Mike Watts, MD, FSIR, from Atlantic Medical Imaging in New Jersey, presented a practical, real-world approach to performing distal deep venous arterialization (dDVA) in the office-based lab.
Dr Walker comments on the article by Randhawa, Thomas, and Siah entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study”.
Dr Walker comments on the article by Randhawa, Thomas, and Siah entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study”.
McCall Walker, MD; Craig M. Walker, MD, FACC, FACP, FSCAI, FCCP; Sahil A. Parikh, MD, FACC, FSCAI; Matthew T. Finn, MD, MS
In light of recent reports alleging overuse of atherectomy devices, the authors revisit the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
In light of recent reports alleging overuse of atherectomy devices, the authors revisit the guidelines and clinical data as to inform the overall discourse surrounding the appropriate use of these devices.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
Stavros Spiliopoulos, MD, PhD; Stavros Grigoriadis, MD, MSc, PhD; Konstantinos Palialexis, MD, MSc, PhD; Constantine N. Antonopoulos, MD, PhD; George S. Sfyroeras, MD, PhD
A 72-year-old woman with a 10-year history of type 2 DM, arterial hypertension, and hyperlipidemia presented with longstanding lower-extremity IC affecting her left leg.
A 72-year-old woman with a 10-year history of type 2 DM, arterial hypertension, and hyperlipidemia presented with longstanding lower-extremity IC affecting her left leg.
Tom Davis, MD; Peter Dovgan, MD; Eric J. Dippel, MD
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
Alberto Francesco Cereda, MD; Marco Biolcati, MD; Federico Biondi, MD; Marco Stracqualursi, MD; Antonio Gabriele Franchina, MD; Lorenzo Tua, MD; Stefano Lucreziotti, MD
This meta-analysis assesses the association between peak anti-Xa levels and bleeding events in patients treated with apixaban or rivaroxaban.
This meta-analysis assesses the association between peak anti-Xa levels and bleeding events in patients treated with apixaban or rivaroxaban.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report discusses a 67-year-old man with lifestyle-limiting claudication and a resting left ankle-brachial index of 0.52 secondary to a 60-mm, moderately-to-severely calcified superficial femoral artery CTO.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
This case report describes the use of the DETOUR system to successfully treat a dense calcific TASC D lesion with associated tissue loss and ultimate limb salvage.
Stavros Spiliopoulos, MD, PhD; Stavros Grigoriadis, MD, MSc, PhD; Konstantinos Palialexis, MD, MSc, PhD; Constantine N. Antonopoulos, MD, PhD; George S. Sfyroeras, MD, PhD
A 72-year-old woman with a 10-year history of type 2 DM, arterial hypertension, and hyperlipidemia presented with longstanding lower-extremity IC affecting her left leg.
A 72-year-old woman with a 10-year history of type 2 DM, arterial hypertension, and hyperlipidemia presented with longstanding lower-extremity IC affecting her left leg.
Attorney Jason Greis discusses how AI-driven downcoding is affecting physician practices, highlighting repeated audits or downcoding of the same CPT codes as key warning signs.
Attorney Jason Greis discusses how AI-driven downcoding is affecting physician practices, highlighting repeated audits or downcoding of the same CPT codes as key warning signs.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
A prediction model combining deep learning, radiomics, and clinical data demonstrated promising performance in predicting disease progression following transarterial chemoembolization in patients with hepatocellular carcinoma.
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
LATHAM, N.Y.--(BUSINESS WIRE)--Oct. 8, 2026-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
SAN DIEGO -- REVA Medical, LLC announced the successful completion of a live case demonstration featuring the MOTIV® sirolimus-eluting bioresorbable vascular scaffold and the presentation of late-breaking clinical results from the...
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Final late-breaking VIVA26 studies reported new data on the Revello™ covered stent for iliac artery disease, Neuroguard IEP carotid stenting outcomes, and early real-world use of the Rotarex™ atherectomy system in CLTI.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Late-breaking VIVA26 studies reported on IVL for calcified PAD, transdermal oxygen therapy after LE revascularization, transcatheter arterialization for no-option CLTI, and DES outcomes in complex femoropopliteal disease.
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Three late-breaking VIVA26 studies reported new data on bleeding risk with ultrasound-facilitated catheter-directed thrombolysis, wearable-based functional recovery after intermediate-high-risk PE, and Laguna Thrombectomy System™ safety and...
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Six late-breaking VIVA26 studies reported new data on sirolimus-based balloon and resorbable scaffold therapies, as well as adjunctive pharmacologic treatment, for patients with PAD and chronic limb-threatening ischemia.
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac...
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients’ everyday recovery.
